Conclusions:IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy. The study will therefore move into Phase 1b with IMU-201 being assessed in combination with atezolizumab. Clinical trial information: NCT04432207.
....nice one!
Ann: IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.8¢ |
Change
-0.013(3.91%) |
Mkt cap ! $67.56M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.5¢ | 30.5¢ | $578.0K | 1.863M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 269724 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 154916 | 8 |
View Market Depth
| Last trade - 15.52pm 23/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |